Slides
Page 1
©2026 Coherus Oncology, Inc. 44TH ANNUAL J.P.MORGAN Healthcare Conference Denny Lanfear, Chairman and CEO OVERCOMING IMMUNE RESISTANCE IN CANCER
Page 2
©2026 Coherus Oncology, Inc. Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as “may,” “will,” “should,” “expect,” “could,” “intend,” “target,” “estimate,” “predict,” or “potential” or the negative of these terms or other similar expressions. These statements include, but are not limited to statements about growth in sales or revenues; ability of any of our pipeline product candidates to be first-to-market, first-to-data or first in-class in the future; expectations about being able to secure funding or to secure non-dilutive funding in future periods; statements about multiplying value; future data readouts or catalysts based on the clinical trials of Coherus Oncology, Inc. (“Coherus Oncology”); market size, market value, addressable market or opportunity and the number of patients or incidence for particular indications; ability for a product candidate to disrupt a market; standard of care expectations; projections for cash runway; future collaborations; the degree of unmet need for particular indications; and the assumptions underlying or relating to such statements. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus Oncology’s actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among other things, the risks and uncertainties inherent with clinical research and commercialization; the risks and uncertainties of the clinical development and regulatory approval process, including the timing of Coherus Oncology’s regulatory filings; the risk that Coherus Oncology is unable to complete commercial transactions in a timely manner or at all; risks and uncertainties in executing collaboration agreements and other joint ventures, including particular risks of working with international partners; the risk of Coherus Oncology’s dependence on an ability to raise funds, which may not be available on acceptable terms or at all; the risks and uncertainties of the degree of market acceptance for Coherus Oncology’s product by physicians, healthcare providers and patients; and the risks and uncertainties of litigation. For a further discussion of these and other factors that could cause Coherus Oncology’s future results to differ materially from any forward-looking statements see the section entitled “Risk Factors” in Coherus’ Quarterly Report on Form 10-Q for the period ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 6, 2025, as updated by Coherus Oncology’s subsequent reports filed with the SEC. Any forward- looking statements speak only as of the date of this presentation and are made based on the current, plans, estimates, good faith beliefs and judgments of Coherus Oncology management, and the reader is cautioned not to rely on any forward-looking statements made by Coherus Oncology. Unless required by law, Coherus Oncology is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. Coherus Oncology’s past performance should not be considered to be a guarantee of future results. LOQTORZI® is a registered trademark of Coherus Oncology. ©2026 Coherus Oncology, Inc. All rights reserved. 2